NASDAQ:MBRX - Moleculin Biotech Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.71 -0.03 (-1.72 %)
(As of 07/16/2018 04:00 PM ET)
Previous Close$1.70
Today's Range$1.70 - $1.71
52-Week Range$1.47 - $3.40
Volume1,300 shs
Average Volume444,595 shs
Market Capitalization$44.84 million
P/E Ratio-3.60
Dividend YieldN/A
Beta-0.87
Moleculin Biotech logoMoleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.

Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MBRX
CUSIPN/A
Phone713-300-5160

Debt

Debt-to-Equity RatioN/A
Current Ratio7.68
Quick Ratio7.68

Price-To-Earnings

Trailing P/E Ratio-3.60
Forward P/E Ratio-3.00
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.81 per share
Price / Book2.11

Profitability

EPS (Most Recent Fiscal Year)($0.47)
Net Income$-9,800,000.00
Net MarginsN/A
Return on Equity-53.51%
Return on Assets-46.88%

Miscellaneous

Employees8
Outstanding Shares25,770,000
Market Cap$44.84

The Truth About Cryptocurrencies

Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech Inc (NASDAQ:MBRX) issued its quarterly earnings data on Tuesday, May, 15th. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.06. View Moleculin Biotech's Earnings History.

What price target have analysts set for MBRX?

1 brokerages have issued 12-month price targets for Moleculin Biotech's stock. Their forecasts range from $8.00 to $8.00. On average, they expect Moleculin Biotech's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 367.8% from the stock's current price. View Analyst Ratings for Moleculin Biotech.

What is the consensus analysts' recommendation for Moleculin Biotech?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Moleculin Biotech's key competitors?

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the folowing people:
  • Mr. Walter V. Klemp, Founder, Chairman, CEO & Pres (Age 58)
  • Mr. Jonathan P. Foster, CFO & Exec. VP (Age 54)
  • Dr. Donald H. Picker, Chief Scientific Officer (Age 72)
  • Ms. Jacqueline Northcut, Consultant (Age 56)
  • Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board

Has Moleculin Biotech been receiving favorable news coverage?

News articles about MBRX stock have trended somewhat negative recently, Accern reports. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Moleculin Biotech earned a media sentiment score of -0.01 on Accern's scale. They also assigned news articles about the company an impact score of 45.76 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.71.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $44.84 million. The company earns $-9,800,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Moleculin Biotech employs 8 workers across the globe.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 2575 WEST BELLFORT SUITE 333, HOUSTON TX, 77054. The company can be reached via phone at 713-300-5160.


MarketBeat Community Rating for Moleculin Biotech (NASDAQ MBRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  100 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about Moleculin Biotech and other stocks. Vote "Outperform" if you believe MBRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.